Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

631

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Cabotegravir (CAB) tablet
DRUG: Rilpivirine (RPV) tablet
DRUG: Cabotegravir - Injectable Suspension (CAB LA)
DRUG: Rilpivirine - Injectable Suspension (RPV LA)
DRUG: ABC/DTG/3TC STR - Tablet
DRUG: DTG Tablet

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]